{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:43:05Z","timestamp":1791585785931,"version":"4.3.4"},"reference-count":141,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s13311-013-0187-4","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T12:14:12Z","timestamp":1364904852000},"page":"459-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"title":["Developing Therapeutic Antibodies for Neurodegenerative Disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Y. Joy","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0187-4_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0187-4_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1007\/s13311-013-0187-4_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","article-title":"Introduction to current and future protein therapeutics: a protein engineering perspective","volume":"317","author":"Carter","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1007\/s13311-013-0187-4_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrn2995","article-title":"Engaging neuroscience to advance translational research in brain barrier biology","volume":"12","author":"Neuwelt","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev.neuro.22.1.11","article-title":"The cell biology of the blood\u2013brain barrier","volume":"22","author":"Rubin","year":"1999","journal-title":"Annu Rev Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-neuro-060909-152829","article-title":"Connecting vascular and nervous system development: angiogenesis and the blood\u2013brain barrier","volume":"33","author":"Tam","year":"2010","journal-title":"Annu Rev Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1083\/jcb.40.3.648","article-title":"Junctions between intimately apposed cell membranes in the vertebrate brain","volume":"40","author":"Brightman","year":"1969","journal-title":"J Cell Biol"},{"key":"10.1007\/s13311-013-0187-4_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1083\/jcb.34.1.207","article-title":"Fine structural localization of a blood\u2013brain barrier to exogenous peroxidase","volume":"34","author":"Reese","year":"1967","journal-title":"J Cell Biol"},{"key":"10.1007\/s13311-013-0187-4_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0031-6997(24)01513-8","article-title":"Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations","volume":"53","author":"Lee","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1007\/s13311-013-0187-4_bib11","first-page":"15","article-title":"Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain","volume":"45","author":"el-Bacha","year":"1999","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1007\/s13311-013-0187-4_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.43.100901.140204","article-title":"The role of drug transporters at the blood\u2013brain barrier","volume":"43","author":"de Boer","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-013-0187-4_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cne.20885","article-title":"Functional effectiveness of the blood\u2013brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica)","volume":"496","author":"Ek","year":"2006","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/325253a0","article-title":"Astrocytes induce blood\u2013brain barrier properties in endothelial cells","volume":"325","author":"Janzer","year":"1987","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0187-4_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0012-1606(81)90382-1","article-title":"Developing nervous tissue induces formation of blood\u2013brain barrier characteristics in invading endothelial cells: a study using quail\u2013chick transplantation chimeras","volume":"84","author":"Stewart","year":"1981","journal-title":"Dev Biol"},{"key":"10.1007\/s13311-013-0187-4_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.brainresrev.2005.07.004","article-title":"The critical component to establish in vitro BBB model: pericyte","volume":"50","author":"Lai","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1007\/s13311-013-0187-4_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1023\/A:1026406528530","article-title":"Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood\u2013brain barrier","volume":"17","author":"Gaillard","year":"2000","journal-title":"Pharm Res"},{"issue":"Suppl 3","key":"10.1007\/s13311-013-0187-4_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2202-9-S3-S2","article-title":"Developing drugs that can cross the blood\u2013brain barrier: applications to Alzheimer's disease","volume":"9","author":"Banks","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0187-4_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood\u2013brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0187-4_bib21","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","article-title":"Macromolecular permeability across the blood-nerve and blood\u2013brain barriers","volume":"91","author":"Poduslo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/BF01466734","article-title":"Protein size and cerebrospinal fluid composition","volume":"52","author":"Felgenhauer","year":"1974","journal-title":"Klin Wochenschr"},{"key":"10.1007\/s13311-013-0187-4_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: new developments and future challenges","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2013pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib25","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0196-9781(02)00261-9","article-title":"Passage of amyloid beta protein antibody across the blood\u2013brain barrier in a mouse model of Alzheimer's disease","volume":"23","author":"Banks","year":"2002","journal-title":"Peptides"},{"key":"10.1007\/s13311-013-0187-4_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.05.005","article-title":"Anti-amyloid beta protein antibody passage across the blood\u2013brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment","volume":"206","author":"Banks","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib27","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","article-title":"Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy","volume":"31","author":"Wang","year":"2011","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib28","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","article-title":"Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta","volume":"29","author":"Yamada","year":"2009","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib29","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0187-4_bib30","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0187-4_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.expneurol.2012.07.022","article-title":"Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice","volume":"238","author":"Bard","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib32","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","article-title":"The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential","volume":"29","author":"Vassar","year":"2009","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0187-4_bib34","first-page":"415","article-title":"Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy","volume":"5","author":"Nitsch","year":"2008","journal-title":"Neurother J Am Soc Exp NeuroTher"},{"key":"10.1007\/s13311-013-0187-4_bib35","doi-asserted-by":"crossref","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0187-4_bib36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","article-title":"The genetics of Alzheimer disease: back to the future","volume":"68","author":"Bertram","year":"2010","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0187-4_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0187-4_bib39","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature08538","article-title":"Multimodal techniques for diagnosis and prognosis of Alzheimer's disease","volume":"461","author":"Perrin","year":"2009","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0187-4_bib40","doi-asserted-by":"crossref","first-page":"e31302","DOI":"10.1371\/journal.pone.0031302","article-title":"Trans-synaptic spread of tau pathology in vivo","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0187-4_bib41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","article-title":"Propagation of tau pathology in a model of early Alzheimer's disease","volume":"73","author":"de Calignon","year":"2012","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-013-0187-4_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"key":"10.1007\/s13311-013-0187-4_bib44","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/hmg\/10.12.1317","article-title":"BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics","volume":"10","author":"Roberds","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0187-4_bib45","first-page":"399","article-title":"beta-Secretase as a therapeutic target for Alzheimer's disease","volume":"5","author":"Ghosh","year":"2008","journal-title":"Neurother J Am Soc Exp NeuroTher"},{"issue":"Suppl 1","key":"10.1007\/s13311-013-0187-4_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing beta-secretase inhibitors for treatment of Alzheimer's disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib47","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","article-title":"Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor","volume":"31","author":"May","year":"2011","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1044-7431(03)00035-6","article-title":"Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice","volume":"22","author":"Koike","year":"2003","journal-title":"Mol Cell Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib49","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1523\/JNEUROSCI.20-18-06898.2000","article-title":"Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons","volume":"20","author":"Koike","year":"2000","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib50","doi-asserted-by":"crossref","first-page":"e21908","DOI":"10.1371\/journal.pone.0021908","article-title":"Knock-down of cathepsin D affects the retinal pigment epithelium, impairs swim-bladder ontogenesis and causes premature death in zebrafish","volume":"6","author":"Follo","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0187-4_bib51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/emmm.201101084","article-title":"beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment","volume":"4","author":"Cai","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1007\/s13311-013-0187-4_bib52","doi-asserted-by":"crossref","first-page":"38408","DOI":"10.1074\/jbc.M112.415505","article-title":"Beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects","volume":"287","author":"Hitt","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0187-4_bib53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1326-6-88","article-title":"The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb","volume":"6","author":"Rajapaksha","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-013-0187-4_bib54","doi-asserted-by":"crossref","first-page":"8677","DOI":"10.1074\/jbc.M110.194860","article-title":"Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1","volume":"286","author":"Zhou","year":"2011","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"10.1007\/s13311-013-0187-4_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"'Clinical trials in Alzheimer's disease': immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-013-0187-4_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0187-4_bib59","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1007\/s13311-013-0187-4_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib62","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib63","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"10.1007\/s13311-013-0187-4_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1007\/s13311-013-0187-4_bib65","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","article-title":"Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift","volume":"69","author":"Golde","year":"2011","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib67","doi-asserted-by":"crossref","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0187-4_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt59","article-title":"Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease","volume":"3","author":"Bateman","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.1007\/s13311-013-0187-4_bib69","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer's disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"10.1007\/s13311-013-0187-4_bib70","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0187-4_bib71","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","article-title":"Florbetapir PET analysis of amyloid-\u03b2 deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study","volume":"11","author":"Fleisher","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-013-0187-4_bib73","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1523\/JNEUROSCI.2569-11.2011","article-title":"In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice","volume":"31","author":"Yamada","year":"2011","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib74","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib75","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","article-title":"Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model","volume":"30","author":"Boutajangout","year":"2010","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib76","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.expneurol.2010.05.010","article-title":"Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice","volume":"224","author":"Boimel","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib77","doi-asserted-by":"crossref","first-page":"e26860","DOI":"10.1371\/journal.pone.0026860","article-title":"Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice","volume":"6","author":"Bi","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0187-4_bib78","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0187-4_bib79","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib80","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of Tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0187-4_bib81","article-title":"100 years of Lewy pathology","author":"Goedert","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib82","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib83","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0187-4_bib84","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates","volume":"25","author":"Lee","year":"2005","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib85","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-013-0187-4_bib86","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib87","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0187-4_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-013-0187-4_bib89","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0187-4_bib90","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/NEN.0b013e3181f4a90a","article-title":"Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice","volume":"69","author":"Takeuchi","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-013-0187-4_bib91","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1073\/pnas.0606201104","article-title":"Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis","volume":"104","author":"Urushitani","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2009.01.025","article-title":"Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies","volume":"209","author":"Alexandrenne","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-013-0187-4_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","article-title":"Immunization delays the onset of prion disease in mice","volume":"161","author":"Sigurdsson","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-013-0187-4_bib94","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0187-4_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0006-8993(87)90236-8","article-title":"Blood\u2013brain barrier transcytosis of insulin in developing rabbits","volume":"420","author":"Duffy","year":"1987","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0187-4_bib96","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI119125","article-title":"Human blood\u2013brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels","volume":"99","author":"Golden","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-013-0187-4_bib97","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.86.12.4761","article-title":"Blood\u2013brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein","volume":"86","author":"Triguero","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib98","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1046\/j.1471-4159.1996.66041599.x","article-title":"Polyamine modification increases the permeability of proteins at the blood-nerve and blood\u2013brain barriers","volume":"66","author":"Poduslo","year":"1996","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herve","year":"2008","journal-title":"AAPS J"},{"key":"10.1007\/s13311-013-0187-4_bib100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/10611860400015936","article-title":"Nanoparticle surface charges alter blood\u2013brain barrier integrity and permeability","volume":"12","author":"Lockman","year":"2004","journal-title":"J Drug Target"},{"key":"10.1007\/s13311-013-0187-4_bib101","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11095-007-9374-5","article-title":"Contribution of carrier-mediated transport systems to the blood\u2013brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development","volume":"24","author":"Ohtsuki","year":"2007","journal-title":"Pharm Res"},{"key":"10.1007\/s13311-013-0187-4_bib102","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 [(+\/\u2212)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-013-0187-4_bib103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0006-8993(99)01387-6","article-title":"L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4","volume":"829","author":"Gomes","year":"1999","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0187-4_bib104","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/0026-0495(87)90099-0","article-title":"Human blood\u2013brain barrier transferrin receptor","volume":"36","author":"Pardridge","year":"1987","journal-title":"Metab Clin Exp"},{"key":"10.1007\/s13311-013-0187-4_bib105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006948027674","article-title":"Transferrin and transferrin receptor function in brain barrier systems","volume":"20","author":"Moos","year":"2000","journal-title":"Cell Mol Neurobiol"},{"key":"10.1007\/s13311-013-0187-4_bib106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0012-1606(86)90321-0","article-title":"Differentiation-dependent expression of proteins in brain endothelium during development of the blood\u2013brain barrier","volume":"117","author":"Risau","year":"1986","journal-title":"Dev Biol"},{"key":"10.1007\/s13311-013-0187-4_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0022-510X(90)90183-N","article-title":"Transferrin receptors in rat central nervous system. An immunocytochemical study","volume":"98","author":"Giometto","year":"1990","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-013-0187-4_bib108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-3806(86)90111-2","article-title":"Immunocytochemical distribution of transferrin and its receptor in the developing chicken nervous system","volume":"395","author":"Oh","year":"1986","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0187-4_bib109","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1073\/pnas.83.17.6445","article-title":"Intracellular pools of transferrin receptors result from constitutive internalization of unoccupied receptors","volume":"83","author":"Ajioka","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm1315","article-title":"Endocytic recycling","volume":"5","author":"Maxfield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-013-0187-4_bib111","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1073\/pnas.92.7.2820","article-title":"Transferrin-antibody fusion proteins are effective in brain targeting","volume":"92","author":"Shin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/10611860600612953","article-title":"Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles","volume":"14","author":"Mishra","year":"2006","journal-title":"J Drug Target"},{"key":"10.1007\/s13311-013-0187-4_bib113","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood\u2013brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0022-3565(25)20567-5","article-title":"Selective transport of an anti-transferrin receptor antibody through the blood\u2013brain barrier in vivo","volume":"259","author":"Pardridge","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-013-0187-4_bib115","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)35388-1","article-title":"Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood\u2013brain barrier in mouse","volume":"292","author":"Lee","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-013-0187-4_bib116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(00)03108-5","article-title":"Conjugation of brain-derived neurotrophic factor to a blood\u2013brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin","volume":"889","author":"Zhang","year":"2001","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0187-4_bib117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.8420006","article-title":"Blood\u2013brain barrier penetration and in vivo activity of an NGF conjugate","volume":"259","author":"Friden","year":"1993","journal-title":"Science"},{"key":"10.1007\/s13311-013-0187-4_bib118","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1073\/pnas.91.19.9077","article-title":"Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease","volume":"91","author":"Kordower","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0187-4_bib119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s004180050266","article-title":"Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody","volume":"110","author":"Kissel","year":"1998","journal-title":"Histochem Cell Biol"},{"key":"10.1007\/s13311-013-0187-4_bib120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp1003515","article-title":"Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain","volume":"8","author":"Zhou","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1007\/s13311-013-0187-4_bib121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1471-4159.2001.00541.x","article-title":"Restricted transport of anti-transferrin receptor antibody (OX26) through the blood\u2013brain barrier in the rat","volume":"79","author":"Moos","year":"2001","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jcp.36.5.539","article-title":"Transferrin receptors in human tissues: their distribution and possible clinical relevance","volume":"36","author":"Gatter","year":"1983","journal-title":"J Clin Pathol"},{"key":"10.1007\/s13311-013-0187-4_bib123","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0187-4_bib124","doi-asserted-by":"crossref","first-page":"14663","DOI":"10.1016\/S0021-9258(18)47847-7","article-title":"A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis","volume":"262","author":"McClain","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0187-4_bib125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1016244500596","article-title":"Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood\u2013brain barrier in vivo in the primate","volume":"12","author":"Pardridge","year":"1995","journal-title":"Pharm Res"},{"key":"10.1007\/s13311-013-0187-4_bib126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bit.21120","article-title":"Humanization of anti-human insulin receptor antibody for drug targeting across the human blood\u2013brain barrier","volume":"96","author":"Boado","year":"2007","journal-title":"Biotechnol Bioeng"},{"key":"10.1007\/s13311-013-0187-4_bib127","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI119708","article-title":"Drug targeting of a peptide radiopharmaceutical through the primate blood\u2013brain barrier in vivo with a monoclonal antibody to the human insulin receptor","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-013-0187-4_bib128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/bc060349x","article-title":"Fusion antibody for Alzheimer's disease with bidirectional transport across the blood\u2013brain barrier and abeta fibril disaggregation","volume":"18","author":"Boado","year":"2007","journal-title":"Bioconjugate Chem"},{"key":"10.1007\/s13311-013-0187-4_bib129","first-page":"465","article-title":"Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer","volume":"9","author":"Zhang","year":"2003","journal-title":"Mol Vis"},{"key":"10.1007\/s13311-013-0187-4_bib130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/bit.21764","article-title":"GDNF fusion protein for targeted-drug delivery across the human blood\u2013brain barrier","volume":"100","author":"Boado","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"10.1007\/s13311-013-0187-4_bib131","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/j.1460-2075.1995.tb07221.x","article-title":"39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein","volume":"14","author":"Bu","year":"1995","journal-title":"EMBO J"},{"key":"10.1007\/s13311-013-0187-4_bib132","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2007.08.008","article-title":"Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1","volume":"56","author":"Liu","year":"2007","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0187-4_bib133","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1517\/17425247.2.2.299","article-title":"Targeted delivery across the blood\u2013brain barrier","volume":"2","author":"Gaillard","year":"2005","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1007\/s13311-013-0187-4_bib134","doi-asserted-by":"crossref","first-page":"e2469","DOI":"10.1371\/journal.pone.0002469","article-title":"A unique carrier for delivery of therapeutic compounds beyond the blood\u2013brain barrier","volume":"3","author":"Karkan","year":"2008","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0187-4_bib135","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2011.427","article-title":"Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1","volume":"105","author":"Bertrand","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1007\/s13311-013-0187-4_bib136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0006-8993(95)00735-9","article-title":"Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain","volume":"691","author":"Tooyama","year":"1995","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0187-4_bib137","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1538-7836.2005.01371.x","article-title":"Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability","volume":"3","author":"Lillis","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1007\/s13311-013-0187-4_bib138","first-page":"240","article-title":"Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood\u2013brain barrier endothelium","volume":"16","author":"Muruganandam","year":"2002","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1007\/s13311-013-0187-4_bib139","first-page":"435","article-title":"Phage display technology for identifying specific antigens on brain endothelial cells","volume":"89","author":"Tanha","year":"2003","journal-title":"Methods Mol Med"},{"key":"10.1007\/s13311-013-0187-4_bib140","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1471-4159.2005.03463.x","article-title":"The blood\u2013brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells","volume":"95","author":"Abulrob","year":"2005","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0187-4_bib141","doi-asserted-by":"crossref","first-page":"e39036","DOI":"10.1371\/journal.pone.0039036","article-title":"A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys","volume":"7","author":"Ohshima-Hosoyama","year":"2012","journal-title":"PLoS One"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0187-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0187-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:52:27Z","timestamp":1761807147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1878747923012369"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0187-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing Therapeutic Antibodies for Neurodegenerative Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0187-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}